Vanguard Group
ELOX

Vanguard Group’s Eloxx Pharmaceuticals, Inc. Common Stock ELOX Stock Holding History

Vanguard Group’s Portfolio ELOX Stock Details ELOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,786
Closed -$100K – 4597
2023
Q3 		$100K Buy
20,786
+100
+0.5% +$560 ﹤0.01% 4347
2023
Q2 		$80.5K Hold
20,686
– – ﹤0.01% 4408
2023
Q1 		$51.9K Sell
20,686
-19,727
-49% -$71.4K ﹤0.01% 4464
2022
Q4 		$73.6K Sell
40,413
-27,200
-40% -$131K ﹤0.01% 4417
2022
Q3 		$459K Sell
67,613
-2,942
-4% -$35.4K ﹤0.01% 4241
2022
Q2 		$762K Hold
70,555
– – ﹤0.01% 4173
2022
Q1 		$1.58M Sell
70,555
-5,382
-7% -$106K ﹤0.01% 4054
2021
Q4 		$2.14M Sell
75,937
-239
-0.3% -$10.4K ﹤0.01% 4006
2021
Q3 		$4.97M Sell
76,176
-212
-0.3% -$13.1K ﹤0.01% 3666
2021
Q2 		$6.08M Buy
76,388
+46,571
+156% +$3.89M ﹤0.01% 3487
2021
Q1 		$3.96M Buy
29,817
+377
+1% +$57.6K ﹤0.01% 3649
2020
Q4 		$4.69M Buy
29,440
+351
+1% +$42.9K ﹤0.01% 3388
2020
Q3 		$3.06M Sell
29,089
-277
-0.9% -$33.2K ﹤0.01% 3354
2020
Q2 		$3.56M Buy
29,366
+598
+2% +$67.7K ﹤0.01% 3244
2020
Q1 		$2.25M Buy
28,768
+242
+0.8% +$39.4K ﹤0.01% 3269
2019
Q4 		$8.4M Buy
28,526
+117
+0.4% +$23.6K ﹤0.01% 2944
2019
Q3 		$5.14M Buy
28,409
+1,065
+4% +$303K ﹤0.01% 3131
2019
Q2 		$10.9M Buy
27,344
+2,153
+9% +$906K ﹤0.01% 2809
2019
Q1 		$11.8M Buy
25,191
+1,061
+4% +$516K ﹤0.01% 2741
2018
Q4 		$11.6M Buy
24,130
+2,700
+13% +$1.49M ﹤0.01% 2703
2018
Q3 		$14.6M Buy
21,430
+8,033
+60% +$5.14M ﹤0.01% 2739
2018
Q2 		$9.15M Buy
+13,397
New +$8.68M ﹤0.01% 2945

Other funds holding ELOX

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Vanguard Group's ELOX Position: Q4 2023 in Review

Vanguard Group sold out of Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) in Q4 2023, closing a stake of 20,786 shares — an estimated $100K sold.

Vanguard Group first reported a position in ELOX in Q2 2018 and held it in 22 quarters. The position peaked at $14.6M in Q3 2018. 4 funds tracked by Wall St. Rank hold ELOX as of Q4 2023.

  • Vanguard Group reported no remaining Eloxx Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Vanguard Group sold 20,786 Eloxx Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $100K.
  • Vanguard Group first reported a position in Eloxx Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
  • Vanguard Group's Eloxx Pharmaceuticals, Inc. Common Stock position peaked at $14.6M in Q3 2018.
  • 4 funds tracked by Wall St. Rank held Eloxx Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Vanguard Group's 13F filing for Q4 2023, filed 14 Feb 2024.